Arcadia Biosciences receives Nasdaq delisting notice for equity shortfall

Arcadia Biosciences, Inc.

On Aug 31, 2026, Nasdaq notified Arcadia that stockholders' equity of $633,000 as of Jun 30, 2026, is below the $2.5M minimum required by Listing Rule 5550(b)(1).
Company has until Oct 15, 2026 (45 days) to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension if plan accepted.
If plan rejected, Arcadia can appeal to a Nasdaq Hearings Panel, which ordinarily stays suspension pending decision.
Stock continues trading on Nasdaq Capital Market pending compliance review; no immediate delisting impact.
CEO Thomas J. Schaefer signed the filing; company evaluating alternatives to regain compliance.

Featured in Daily 8-K Digest

Selected #5 for 2026-09-04. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.